Summary
May 2008, Vol. 9, No. 7, Pages 1071-1085 , DOI 10.1517/14656566.9.7.1071

Recommendations and treatment strategies for the management of acute ischemic stroke

Tomás Segura1,2 MD PhD, Sergio Calleja3 MD PhD & Joaquin Jordan4 PhD
1Associate Professor Hospital General Universitario de Albacete, Department of Neurology, Albacete-02006, Spain
2Associate Professor Universidad Castilla-La Mancha, Department of Medical Sciences, Facultad de Medicina., Albacete-02006, Spain +34 67 59 71 00; +34 67 59 74 40;
3Hospital Universitario Central de Asturias, Department of Neurology, Oviedo, Spain
4Associate Professor Universidad Castilla-La Mancha, Grupo de Neurofarmacología, Department of Medical Sciences, Facultad de Medicina., 02006 Albacete, Spain
Author for correspondence



Background: Stroke is one of the leading causes of mortality and disability worldwide. From the establishment of the penumbra concept, ischemic stroke has been recognized as a dynamic process and two main therapeutic strategies have been designed: one that tries to reopen the occluded artery and the second aims to protect the penumbra brain tissue until the physiologic mechanisms–or the treatment–stop the ischemia. Objective: To review the most recent, high-quality evidence for acute stroke treatment. Methods: Systematic review of relevant published studies focused in several aspects of acute ischemic stroke management, from neuroprotection to thrombolysis. Conclusions: After the publication of NINDS rt-PA study, the classical nihilistic approach to ischemic stroke started to change and thrombolytic treatment was approved in the treatment of patients with acute ischemic stroke presenting within 3 h from onset of symptoms. Advances in this field are proceeding on several fronts, including the use of next-generation plasminogen activators and glycoprotein IIb/IIIa inhibitors, refined patient selection with advanced magnetic resonance imaging sequences, endovascular approaches to thrombolysis and thrombectomy, and adjuvant use of ultrasound. Abrupt deprivation of oxygen and glucose to neuronal tissues elicits a series of pathologic cascades, leading to the spread of neuronal death. Of the numerous pathways identified, excessive activation of glutamate receptors, accumulation of intracellular Ca2+ cations, abnormal recruitment of inflammatory cells, excessive production of free radicals and initiation of pathologic apoptosis are believed to play critical roles in ischemic damage, especially in the penumbral zone. Several neuroprotective agents designed to block these cascades have been investigated in animal models of cerebral ischemia and numerous agents have been found to reduce infarct size. However, translation of neuroprotective benefits from the laboratory bench to the emergency room has not been successful. Other measures, such as the relevance of body position in the acute phase of stroke, anticoagulant and antiplatelet agents or the effects of statins and antihypertensive therapy, are discussed in this paper, with an overview of the relevance of stroke units.

Full Text | PDF (1351 KB) | PDF Plus (1320 KB)

Users who read this article also read:

Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure
Mara T Slawsky, Michael M Givertz
Expert Opinion on Pharmacotherapy, Feb 2009, Vol. 10, No. 2, Pages 311-322.
Summary | Full Text | PDF (439 KB) | PDF Plus (325 KB) | Add to Favorites | Related 
Edaravone for the treatment of acute cerebral infarction: role of endothelium-derived nitric oxide and oxidative stress
Yukihito Higashi
Expert Opinion on Pharmacotherapy, Feb 2009, Vol. 10, No. 2, Pages 323-331.
Summary | Full Text | PDF (293 KB) | PDF Plus (229 KB) | Add to Favorites | Related 
Lenalidomide: a novel anticancer drug with multiple modalities
Christine Galustian, Angus Dalgleish
Expert Opinion on Pharmacotherapy, Jan 2009, Vol. 10, No. 1, Pages 125-133.
Summary | Full Text | PDF (388 KB) | PDF Plus (337 KB) | Add to Favorites | Related 
Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis
Volker Gross
Expert Opinion on Pharmacotherapy, May 2008, Vol. 9, No. 7, Pages 1257-1265.
Summary | Full Text | PDF (147 KB) | PDF Plus (219 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (1351 KB)
View PDF Plus (1320 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
Tomás Segura
Sergio Calleja
Joaquin Jordan
Keywords:
clinical trial
ischemia
neuroprotection
stroke management
thrombolysis